A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates.

@article{Qiao2012ARC,
  title={A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates.},
  author={Jie Qiao and Guang-xiu Lu and Hong Wei Zhang and Hua Chen and Caihong Ma and Jan I Olofsson and H H G Witjes and E. W. Heijnen and Bernadette Mannaerts},
  journal={Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology},
  year={2012},
  volume={28 10},
  pages={800-4}
}
Gonadotropin-releasing hormone (GnRH) antagonists for controlled ovarian stimulation (COS) were only recently introduced into China. The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120). The primary end point was the amount of recombinant follicle-stimulating hormone (rFSH) required to meet the human… CONTINUE READING